| (Values in U.S. Thousands) | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 |
| Sales | 28,750 | 68,550 | 44,150 | 29,440 | 27,460 |
| Sales Growth | -58.06% | +55.27% | +49.97% | +7.21% | -52.57% |
| Net Income | -16,060 | -7,550 | -1,820 | -8,270 | -13,960 |
| Net Income Growth | -112.72% | -314.84% | +77.99% | +40.76% | -357.09% |
Olink Holding Ab [Publ] ADR (OLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Olink Holding AB provides a platform of products and services which are deployed across major biopharmaceutical companies and clinical and academic institutions to deepen the understanding of real-time human biology. It operates principally in Europe, North America and Asia. Olink Holding AB is headquartered in Uppsala, Sweden.
Fiscal Year End Date: 12/31